CA-GLOBALLOGIC-INC.
11.1.2023 12:01:37 CET | Business Wire | Press release
GlobalLogic Inc., a Hitachi Group company and Digital Engineering leader, announced today that it has been named an overall Leader in the Zinnov Zones for ER&D Services 2022 Ratings. The report provides a 360-degree assessment of engineering research and development (ER&D) service providers, identifying their prowess and scalability across key markets and technologies. It is leveraged by company decision makers seeking to identify vetted service providers to support a wide range of engineering projects. Such resources are increasingly more important as investment in digital transformation rises rapidly across all industries to satisfy a growing demand for intelligent, connected, and data-driven experiences for consumers and company employees alike.
Zinnov is a global management consulting and strategy advisory firm with 20+ years of experience. As part of its annual ER&D Services Zinnov Zones ratings exercise, the company evaluates more than 50 global service providers across multiple verticals, micro-verticals, and geographies. GlobalLogic’s earned position as an overall leader indicates the digital engineering firm has demonstrated itself to be an Established, Expansive company when compared to its peers—labels specifically measuring:
- Established: proven specialization; R&D practice maturity (depth and maturity of services); innovation and IP; ecosystem linkages
- Expansive: scale and scalability; number of verticals serviced; client spread/diversification
Validating its overall leadership recognition, GlobalLogic was rated in the leadership zone for the following verticals and technologies:
- Automotive
- Consumer Software
- Data & AI Engineering
- Enterprise Software
- Experience Engineering
- Telecommunications
- Telehealth
The 2022 edition of the Zones ratings marks GlobalLogic’s seventh year earning a spot in the ER&D Services Ratings’ general leader quadrant, having first placed there in 2016. While GlobalLogic first moved to an overall leadership position three years ago, it has since moved up in its rating and earned higher leadership zone positions in several sub-categories listed above.
“The recognition received in the Zinnov Zones evaluation is a direct testament to the ingenuity, commitment, and skills displayed by our team members around the world,” said Arya Barirani, Chief Marketing Officer, GlobalLogic. “From our perspective, this rating acknowledges our continued ability to deepen our foothold in a wide variety of markets. It also acknowledges our dedication to broadening our experience in technologies that drive next- gen digital transformations. These investments in our people, training, and facilities are all designed to help us better serve our customers.”
Sidhant Rastogi, Managing Partner, Zinnov, said, “GlobalLogic’s intense focus on building new-age technology capabilities, combined with its digital accelerators and its self-contained innovation labs, has helped the firm drive high value transformation for its customers. GlobalLogic continues to strengthen its digital core through strategic acquisitions like Fortech, which has enabled it to expand its portfolio of offerings across technologies and geographies. A well-articulated growth strategy and a data-driven approach across its wide-spectrum of Digital Engineering Services offerings has helped GlobalLogic firmly anchor its leadership position in the 2022 Zinnov Zones ER&D ratings.”
The 2022 ER&D Services Ratings report as well as prior year reports can be found here: https://zinnovzones.com/ratings/e-r-and-d-services/overall/2022.
About Zinnov
Founded in 2002, Zinnov is a global management consulting and strategy advisory firm with a presence in New York, Santa Clara, Seattle, Houston, Bangalore, Gurgaon, Paris, and Pune. With a team of experienced consultants, subject matter experts, and research professionals, Zinnov has partnered with Global Enterprises, Fortune 2000 companies, Global System Integrators, and Private Equity firms across their value creation journeys to develop actionable insights – across revenue, talent, innovation, scale, and optimization. For more information, visit Zinnov.
About GlobalLogic
GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom